美國(guó)MEFs Oct4-GFP報(bào)告基因小鼠胚胎成纖維細(xì)胞

美國(guó)PrimCells干細(xì)胞：PrimCells提供多種報(bào)告基因敲進(jìn)的小鼠胚胎干細(xì)胞，該類細(xì)胞皆在原始基因座上敲入熒光報(bào)告基因，從而使熒光蛋白的表達(dá)能真實(shí)反映原基因座附近的表達(dá)調(diào)控狀況。該類細(xì)胞作為研究胚胎干細(xì)胞自更新和定向分化的有力工具，受到多家有名研究所研究人員的青睞。

Newly In Stock!

美國(guó)MEFs Oct4-GFP報(bào)告基因小鼠胚胎成纖維細(xì)胞

Introduction:

Primary mouse embryonic fibroblasts (MEFs) are typically derived from E13.5 mouse embryos. They are relatively easy to culture and maintain and have robust proliferation rate. MEFs can be powerful tools to study gene functions especially when comparison experiments between wild-type and knockout cells from the same liter are required. Meanwhile, MEFs have also been used as feeder cells to support growth of embryonic stem cells from a variety of species1. More recently, MEFs from reporter transgenic mice were used for assessing gene function during reprogramming of fibroblasts to induced pluripotent stem cells (iPSCs) ².

PrimCells is proud to isolate and provide the primary cultures of embryonic fibroblasts from transgenic mice carrying IRES-GFP gene in their endogenous Pou5f1 (Oct4) locus. When these cells are fully reprogrammed, iPSCs will become GFP+, which could be a powerful tool for chemical screening or gene functional studies in order to develop more efficient reprogramming technology.

Figure 1 | Successfully reprogrammed iPSCs become GFP positive

美國(guó)PrimCells品牌介紹

PrimCells是位于美國(guó)加州圣迭戈的一家專業(yè)致力于細(xì)胞產(chǎn)品研發(fā)和解決方案提供的業(yè)內(nèi)技術(shù)。

公司匯集了*的生物醫(yī)藥技術(shù)專家，獨(dú)立開發(fā)了多項(xiàng)原代細(xì)胞和干細(xì)胞相關(guān)的專有技術(shù)。 公司以“細(xì)胞研究的優(yōu)選擇"為宗旨，自主研發(fā)超過70種創(chuàng)新產(chǎn)品，多個(gè)特種細(xì)胞市場(chǎng)的空白。例如其誘導(dǎo)性表達(dá)細(xì)胞庫(kù)和高效3D皮膚培養(yǎng)系統(tǒng)，皆為該類產(chǎn)品目前市場(chǎng)上少數(shù)的規(guī)?；?yīng)商。此外，公司以高質(zhì)量的數(shù)據(jù)與快速穩(wěn)定的項(xiàng)目完成時(shí)間，長(zhǎng)期為多家制藥公司提供解決方案，獲得用戶廣泛贊譽(yù)。  

PrimCells產(chǎn)品線：

1. 報(bào)告基因干細(xì)胞        2. 原代細(xì)胞（含報(bào)告基因原代細(xì)胞）               3. 誘導(dǎo)性穩(wěn)定細(xì)胞株

4. 人源重組蛋白               5.   創(chuàng)新型培養(yǎng)試劑      

PrimCells 解決方案

1.誘導(dǎo)性穩(wěn)定細(xì)胞株開發(fā) 2. 原代細(xì)胞開發(fā) 3. 藥物體外毒理和效能測(cè)試 4. 3D-皮膚培養(yǎng)

PrimCells合作伙伴及客戶:

A．生物制藥公司：輝瑞(Pfizer), 諾華(Novartis), 禮來(Eli2  Lilly),. Amgen, EMD Millipore, Regeneron等公司的毒理和醫(yī)藥研發(fā)部門

B．科研機(jī)構(gòu)：冷泉港實(shí)驗(yàn)室，哈佛醫(yī)學(xué)院, 麻省理工（MIT）,， UCSF, NYU, Salk, UIUC, USC等